ArticleBritish journal of cancer2013
Using macrophage activation to augment immunotherapy of established tumours.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 59 citations in OpenAlex.
- Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.The Journal of clinical investigation · 2014Trial
- Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment.Molecular cancer · 2025Review
- Melittin derived peptide-drug conjugate, M-DM1, inhibits tumor progression and induces effector cell infiltration in melanoma by targeting M2 tumor-associated macrophages.Frontiers in immunology · 2023Article
- Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy.Cancers · 2022Article
- Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages.Cancers · 2022Article
- Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model.Frontiers in immunology · 2022Article
- Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy.Kidney diseases (Basel, Switzerland) · 2022Review
- Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy.Frontiers in cell and developmental biology · 2021Review
- The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy.Acta pharmaceutica Sinica. B · 2020Review
- Caveolin-2 deficiency induces a rapid anti-tumor immune response prior to regression of implanted murine lung carcinoma tumors.Scientific reports · 2019Article
- TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors.Nature communications · 2019Article
- Modeling Macrophage Polarization and Its Effect on Cancer Treatment Success.Open journal of immunology · 2018Article
- Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.Scientific reports · 2018Article
- M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.PloS one · 2018Article
- STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.Cancer research · 2017Article
- Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Clinical & translational immunology · 2017Review
- Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.International journal of molecular sciences · 2017Review
- Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.Oncotarget · 2017Article
- Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.International journal of molecular sciences · 2016Review
- High salt induces anti-inflammatory MΦ2-like phenotype in peripheral macrophages.Biochemistry and biophysics reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundSuccessful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immunotherapy.
methodsWe and others have reported that 5,6-Dimethylxanthenone-4-acetic-acid (DMXAA, Vadimezan) has the ability to change TAM phenotypes, inducing a tumour microenvironment conducive to antitumour immune responses. We therefore combined DMXAA with active immunotherapies, and evaluated anti-tumour efficacy, immune cell phenotypes (flow cytometry), and tumour microenvironment (RT-PCR).
resultsIn several different murine models of immunotherapy for lung cancer, DMXAA-induced macrophage activation significantly augmented the therapeutic effects of immunotherapy. By increasing influx of neutrophils and anti-tumour (M1) macrophages to the tumour, DMXAA altered myeloid cell phenotypes, thus changing the intratumoural M2/non-M2 TAM immunoinhibitory ratio. It also altered the tumour microenvironment to be more pro-inflammatory. Modulating macrophages during immunotherapy resulted in increased numbers, activity, and antigen-specificity of intratumoural CD8(+) T cells. Macrophage depletion reduced the effect of combining immunotherapy with macrophage activation, supporting the importance of TAMs in the combined effect.
conclusionModulating intratumoural macrophages dramatically augmented the effect of immunotherapy. Our observations suggest that addition of agents that activate TAMs to immunotherapy should be considered in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.